Viveve Medical, Inc.

Equities

VIVE

US92852W5013

Advanced Medical Equipment & Technology

Delayed OTC Markets Other stock markets 11:08:07 10/07/2024 pm IST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.50%

2023	InMode Ltd. acquired Intellectual Property Assets of Viveve Medical Inc.	CI
2023	Viveve Medical, Inc.(OTCPK:VIVE) dropped from S&P TMI Index	CI

Viveve Medical, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 13, 2021 at 02:41 am IST

Viveve Medical, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 1.654 million compared to USD 704,000 a year ago. Operating loss was USD 4.945 million compared to USD 4.941 million a year ago. Net loss was USD 4.050 million compared to USD 7.115 million a year ago. Basic loss per share from continuing operations was USD 0.49 compared to USD 5.74 a year ago. For the half year, sales was USD 3.104 million compared to USD 2.008 million a year ago. Operating loss was USD 10.074 million compared to USD 10.769 million a year ago. Net loss was USD 9.841 million compared to USD 13.425 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to USD 13.35 a year ago.

Latest news about Viveve Medical, Inc.

InMode Ltd. acquired Intellectual Property Assets of Viveve Medical Inc.	25/23/25	CI
Viveve Medical, Inc.(OTCPK:VIVE) dropped from S&P TMI Index	23/23/23	CI
Viveve Medical, Inc.(OTCPK:VIVE) dropped from NASDAQ Composite Index	18/23/18	CI
Sector Update: Health Care Stocks Finishing Near Intra-Day Lows	18/23/18	MT
Sector Update: Health Care Stocks Sputtering in Tuesday Trading	18/23/18	MT
Top Midday Decliners	18/23/18	MT
Sector Update: Health Care	18/23/18	MT
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday	17/23/17	MT
Sector Update: Health Care	17/23/17	MT
Investors Digest More Big Bank Earnings, Weighing on US Equity Futures	17/23/17	MT
Weak China GDP Data Weigh on Exchange-Traded Funds, Equity Futures Premarket Tuesday	17/23/17	MT
Top Premarket Decliners	17/23/17	MT
Viveve Medical Fails to Meet Primary Endpoint in Stress Urinary Incontinence Study; Unveils Cut in Workforce; Expects Delisting From Nasdaq	17/23/17	MT
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence	17/23/17	CI
Viveve Medical to Seek Strategic Alternatives	17/23/17	CI
Viveve Medical, Inc. Announces Completion of Pivotal US Pursuit Trial for Female Stress Urinary Incontinence	15/22/15	CI
Transcript : Viveve Medical, Inc., Q3 2022 Earnings Call, Nov 10, 2022	11/22/11
Viveve Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Earnings Flash (VIVE) VIVEVE MEDICAL Posts Q3 Revenue $1.7M	11/22/11	MT
Viveve Medical, Inc. announced that it has received $0.014675 million in funding	27/22/27	CI
Viveve Medical, Inc. announced that it expects to receive $0.014675 million in funding	14/22/14	CI
Viveve Medical, Inc. Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence	04/22/04	CI
Viveve Medical, Inc. Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal Pursuit Trial Readout	27/22/27	CI
Transcript : Viveve Medical, Inc., Q2 2022 Earnings Call, Aug 11, 2022	12/22/12
Viveve Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI

Chart Viveve Medical, Inc.

Duration

Period

More charts

Company Profile

Viveve Medical, Inc. designs, develops, manufactures and markets a platform medical technology, Cryogen-cooled Monopolar RadioFrequency (CMRF). The Companyâs CMRF technology is delivered through a radiofrequency generator, handpiece and treatment tip, which collectively, is referred to as the Viveve System. The Viveve System is marketed for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence (SUI). In the United States, the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis. The Viveve System is cleared for marketing in approximately 48 countries throughout the world, including North America, Asia Pacific, Europe, the Middle East and Latin America countries. The Companyâs wholly owned subsidiaries include Viveve, Inc. and Viveve BV.

Sector

Advanced Medical Equipment & Technology

More about the company

	1st Jan change	Capi.
VIVEVE MEDICAL, INC.	-99.50%	10
THERMO FISHER SCIENTIFIC	+3.05%	20TCr
DANAHER CORPORATION	+6.69%	18TCr
INTUITIVE SURGICAL, INC.	+32.80%	16TCr
BOSTON SCIENTIFIC CORPORATION	+33.20%	11TCr
SIEMENS HEALTHINEERS AG	+4.87%	6.49TCr
EDWARDS LIFESCIENCES CORPORATION	+24.60%	5.65TCr
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-4.03%	4.64TCr
AGILENT TECHNOLOGIES, INC.	-6.59%	3.71TCr
GE HEALTHCARE TECHNOLOGIES INC.	+3.08%	3.61TCr

Other Advanced Medical Equipment & Technology